Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 268

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies

Open access
Steinhoff, Bernhard J., Ben‐Menachem, Elinor, Ryvlin, Philippe, Shorvon, Simon, Kramer, Lynn, Satlin, Andrew, Squillacote, David, Yang, Haichen, Zhu, Jin, Laurenza, Antonio·2013·Epilepsia

Abstract

Summary: Purpose: Three phase III studies (304 [ClinicalTrials.gov identifier: NCT 00699972], 305 [NCT 00699582], 306 [NCT 00700310]) evaluated perampanel, an α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptor antagonist, as adjunctive therapy for refractory partial seizures. We report post hoc analyses of pooled study data by randomized dose. Methods: Patients with partial seizures despite receiving 1–3 antiepileptic drugs were randomized to once‐daily placebo, perampanel 8 or 12 mg (studies 304, 305), or placebo, perampanel 2, 4, or 8 mg (study 306). Studies included a 6‐week baseline period and double‐blind treatment phase (6‐week titration; 13‐week maintenance). Primary end points were median change in partial seizure frequency (baseline vs. double‐blind phase) and percentage of patients achieving ≥50% reduction in seizure frequency (baseline vs. maintenance). Here, these end points, together with secondary, exploratory, and safety end points, were assessed using pooled study data. Key Findings: The pooled intent‐to‐treat analysis set (randomized, treated patients with any seizure data) included 1,478 patients. Median changes in partial seizure frequency were greater with perampanel than placebo (perampanel 4 mg, −23.3%; 8 mg, −28.8%; 12 mg, −27.2%; placebo, −12.8%; p < 0.01, each dose vs. placebo), as were 50% responder rates (perampanel 4 mg, 28.5%; 8 mg, 35.3%; 12 mg, 35.0%; placebo, 19.3%; p < 0.05, each dose vs. placebo). In addition, median changes in complex partial plus secondary generalized seizure frequency were also greater with perampanel than placebo (perampanel 4 mg, −31.2%; 8 mg, −35.6%; 12 mg, −28.6%; placebo, −13.9%). Perampanel was generally well tolerated. The most frequent treatment‐emergent adverse events (TEAE s) were dizziness, somnolence, and headache. Most TEAE s were mild/moderate; relatively few patients experienced severe TEAE s (placebo, 5.4%; perampanel, 8.9%) or serious TEAE s (placebo, 5.0%; perampanel, 5.5%). There were no deaths and no clinically important mean changes in laboratory values, electrocardiography (ECG) findings, or vital signs. Significance: Perampanel reduced partial seizure frequency and improved responder rates compared with placebo, with an acceptable tolerability profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/epi.12212

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 268

Metadata

Authors
Steinhoff, B. J., Ben‐Menachem, E., Ryvlin, P., Shorvon, S., Kramer, L., Satlin, A., Squillacote, D., Yang, H., Zhu, J., & Laurenza, A.
Venue
Epilepsia
Publisher
Wiley
Published
2013-05-10
Volume
54
Issue
8
Pages
1481-1489
ISSN
  • 0013-9580 (ISSN-L)
  • 1528-1167
OpenAlex
W2145520222
Cited by
268
References
13
FWCI
17.65
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies. https://app.cochat.ai/papers/10.1111/epi.12212
The paper
Steinhoff, B. J., Ben‐Menachem, E., Ryvlin, P., Shorvon, S., Kramer, L., Satlin, A., Squillacote, D., Yang, H., Zhu, J., & Laurenza, A. (2013). Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies. Epilepsia. https://doi.org/10.1111/epi.12212

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.